Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02753400 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
A Phase 2 study of Proliferative Diabetic Retinopathy, sponsored by Kubota Vision.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT02753400: Completed Phase 2 study of Proliferative Diabetic Retinopathy, sponsored by Kubota Vision.
NCT02753400 is a Phase 2 study of Proliferative Diabetic Retinopathy that has completed, run by Kubota Vision. The registered enrollment target is 24 participants, below the 212-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02753400, a Phase 2 study of Proliferative Diabetic Retinopathy, has completed, sponsored by Kubota Vision.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.
Primary Outcome
All values for IL-1β were below the lower limit of detection and were recorded as zero. Tests for IP-10 and MCP-1 failed accuracy and stability testing during assay development and were dropped from the study. The assay for PDGF-AA could not be developed.and results were not reported.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG emixustat hydrochloride
Study Locations (1)
California
- Retina Institute of California - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-05 |
| Est. Completion | 2017-12 |
| Phase | Phase 2 |
What the finished NCT02753400 record still lists
NCT02753400 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 212-participant average among 5 other Proliferative Diabetic Retinopathy trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02753400 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT02753400 about?
NCT02753400 is a clinical study titled "Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy". To evaluate the effects of oral emixustat hydrochloride (emixustat) on aqueous humor biomarkers associated with proliferative diabetic retinopathy (PDR) from baseline to week 12.
What is the current status of trial NCT02753400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2016-05. Estimated completion is 2017-12.
What conditions does trial NCT02753400 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy.
What interventions are being tested in trial NCT02753400?
The interventions under investigation include: Placebo (OTHER), emixustat hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02753400?
This trial is sponsored by Kubota Vision, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02753400 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy
ACTIVE NOT RECRUITING · Phase 2
-
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy
COMPLETED · Phase 2
-
Anti-VEGF vs. Prompt Vitrectomy for VH From PDR
COMPLETED · Phase 2
-
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
COMPLETED · Phase 3
-
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia